Clinical Trial

Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This multi-center, observational, post-intervention LTFU study will monitor for safety and efficacy of AAVAnc80- antiVEGF in individuals with vestibular schwannoma who have previously received an intracochlear administration of AAVAnc80-antiVEGF in an interventional clinical trial
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-03-26; most recent amendment 2026-07-15.
Trial Details
NCT Number NCT07503613
Lead Sponsor Akouos, Inc.
Collaborators: Eli Lilly and Company
Conditions Vestibular Schwannoma
Enrollment 100 participants
Start Date 2026-03-02
Primary Completion 2040-04 (estimated)
Study Completion 2040-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-16